MEDS Trxade Health, Inc - 8-K

Item
5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.

Resignation
of Eric Sherb

On
May 26, 2026, Eric Sherb, the Chief Financial Officer (“CFO”) of Scienture Holdings, Inc. (the “Company”), formally
resigned his position as CFO and advised the Company that his resignation was due to personal reasons and not a result of any dispute
or disagreement with the Company, its management, or its board of directors.

Appointment
of Dr. Narasimhan Mani as Interim Chief Financial Officer

In
connection with Mr. Sherb’s resignation, the Company appointed Dr. Narasimhan Mani (age 51) to serve as the Company’s Interim
Chief Financial Officer (“Interim CFO”) effective as of May 26, 2026. Dr. Mani has served as a director and the Co-Chief
Executive Officer and President of the Company since May 2025. In these roles, Dr. Mani has, among others, led, managed, and overseen
the Company’s operations, including its financial operations such as revenue and expense management, financial planning and analysis,
and financial reporting.

There
are no arrangements or understandings between Dr. Mani and any other person pursuant to which he was selected as Interim CFO of the company,
and there are no family relationships between Dr. Mani and any of the Company’s directors or executive officers. Dr. Mani has no
direct or indirect material interest in any existing or currently proposed transaction that would require disclosure under Item 404(a)
of Regulation S-K.

Dr.
Mani is an experienced healthcare professional, having been employed in the pharmaceutical industry for over 25 years with many of those
in senior management positions. In addition to Dr. Mani’s technical pharmaceutical experience, he has served in various financial-focused
roles for life sciences companies and holds an MBA in Finance and Marketing from Columbia Business School. Prior to joining the Company,
Dr. Mani served as the President and Chief Executive Officer for Kesin Pharma Corporation, a specialty pharma company with a focus on
commercializing specialty and brand products. His past roles include serving as the Chief Executive Officer of Xiromed LLC, a generics
and specialty drug product company and as the Vice President, Global Corporate Strategy and Business Development, at Amneal Pharmaceuticals
where he led all the company’s strategic initiatives across Global Strategy, Portfolio Management, Business Development, and Commercial
Operations. His previous experiences also include being the Corporate Finance and Strategic Planning Leader at Johnson & Johnson
in New Brunswick, New Jersey, in the pharmaceutical and medical device sectors. He also worked as a Research Scientist and Product Development
leader during his time at Forest Laboratories and Par Pharmaceuticals. He is an invited member of the Executives-in-Residence at New
Rhein Healthcare Investors, a life-sciences focused private equity firm, and serves on the board of directors at Corsair Pharma, Inc.,
one of their portfolio companies. Dr. Mani’s journey in the pharmaceutical and healthcare space began with his B.Pharm (Hons.)
from BITS, Pilani, India which he completed in 1995. His subsequent graduate degrees include M.S. Analytical Chemistry, from the University
of Oklahoma, Norman in 1998, Ph.D. in Pharmaceutics, from the University of Georgia, Athens in 2003 and his MBA in Finance and Marketing,
from Columbia Business School, New York, NY in 2008. Dr. Mani is also the recipient of the 2021 Outstanding 50 Asian Americans in Business
Award in September 2021.

Ultimately,
the Company believes that Dr. Mani is qualified to serve as Interim CFO because of his relevant educational experience and his extensive
executive leadership and strategic planning experience in the pharmaceutical and healthcare industries—including his background
in performing and overseeing all aspects of financial operations for pharmaceutical companies. Dr. Mani’s employment with the Company
will continue to be subject to his existing employment agreement, as amended, as previously disclosed in the Current Report on Form 8-K
filed by the Company with the Securities and Exchange Commission on October 24, 2025.